BioNexus Gene Lab (BGLC) Total Liabilities (2018 - 2026)

BioNexus Gene Lab's Total Liabilities history runs 9 years deep, the most recent figure standing at $946877.0 for Q1 2026.

• In Q1 2026, Total Liabilities fell 44.57% year-over-year to $946877.0; the TTM figure through Mar 2026 stood at $946877.0 (down 44.57% YoY), while the FY2025 annual figure was $637856.0, down 69.78% from the prior year.
• Total Liabilities came in at $946877.0 for Q1 2026 at BioNexus Gene Lab, up from $637856.0 in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $2.1 million in Q4 2024 to a low of $637856.0 in Q4 2025.
• A 5-year average of $1.6 million and a median of $1.7 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities grew 29.33% in 2023 and tumbled 69.78% in 2025, its largest moves.
• BioNexus Gene Lab's Total Liabilities stood at $2.1 million in 2022, then retreated by 16.06% to $1.7 million in 2023, then advanced by 21.19% to $2.1 million in 2024, then sank by 69.78% to $637856.0 in 2025, then surged by 48.45% to $946877.0 in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $946877.0, $637856.0, and $804966.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison